Clinical research

Scientific publications
Satelia® Cardio

Published studies on remote monitoring of chronic heart failure with Satelia® Cardio: population, methods, results and limitations.

Updated on October 20, 2026
14
peer-reviewed articles since 2022
18,882
patients in the largest cohort (TELESAT-HF)
300+
hospital and community centres in TELESAT-HF

Major results

Nationwide analyses based on French National Health Insurance data (SNDS).

Logo TELESAT-HF
Eur J Heart Fail · 2025 · doi 10.1002/ejhf.3563

TELESAT-HF

HR 0.64All-cause mortality
95% CI 0.59–0.70; p < 0.0001

That is a 36% lower risk of death in monitored patients: an association observed in real life, consistent across sex, age, severity and digital literacy.

Question
Is remote monitoring with Satelia® Cardio associated with all-cause mortality at national scale?
Population
18,882 heart failure patients from more than 300 hospital and community centres: 5,357 monitored, 13,525 on standard care; mean age 71.8.
Methods
Nationwide cohort on SNDS data, from 1 August 2018 to 31 December 2022, propensity score analysis (NCT06312501).
Other results
Heart failure hospitalisations: no significant difference (RR 0.95; 0.89–1.02). Emergency visits: RR 0.83 (0.75–0.92). Time spent in hospital: −2.1%. Intensive care admissions: RR 0.84 (0.74–0.97).
What the study does not show. Observational study: indication bias cannot be ruled out (more adherent patients, better organised teams). It does not establish causality and does not compare remote monitoring solutions with one another. Among outpatients with no prior heart failure hospitalisation, heart failure hospitalisations were more frequent with remote monitoring, with or without long-term illness status (RR 1.30; 95% CI 1.16–1.45 and RR 1.32; 1.07–1.62), as were intensive care admissions (RR 1.25 and 1.61) and, without long-term illness status, emergency visits (RR 1.18); mortality remained lower in these groups (HR 0.62 and 0.75). For patients without long-term illness status, the authors suggest that some controls may not have had heart failure.
Comparable groups at inclusion
71.8 yearsmean age in both groups
67.8%men among monitored patients
300+hospital and community centres
Standard careSatelia® Cardio
Hypertension
86.5%
86.4%
Rhythm disorders
66.5%
65.7%
Coronary heart disease
56.4%
55.6%
Diabetes
32.1%
31.8%
Obesity
28.4%
28.3%
Chronic pulmonary disease
23.1%
23.1%
Moderate or severe renal insufficiency
20.0%
19.9%

Characteristics after propensity score weighting (table 1 of the article). TELESAT-HF, Eur J Heart Fail, 2025.

Survival from index date
Satelia® CardioStandard careHR 0.64 (95% CI 0.59–0.70)
5060708090100%0612182430
Months of follow-up

NNT = 10.5 to prevent one death at 30 months

Kaplan-Meier, curve redrawn from figure 3A of the article (vertical axis from 50%). TELESAT-HF, Eur J Heart Fail, 2025.

All-cause mortality by subgroup
0.41 = standard care
Overall population
HR 0.6495% CI 0.59–0.70−36%
Outpatients without LTI
HR 0.6295% CI 0.55–0.70−38%
Outpatients with LTI
HR 0.7595% CI 0.58–0.95−26%
1 prior hospitalisation
HR 0.5695% CI 0.46–0.68−44%
2 or more prior hospitalisations
HR 0.5295% CI 0.42–0.64−48%

Weighted HR for the overall population, adjusted HRs for subgroups (table 2 of the article). Outpatients: no heart failure hospitalisation in the previous 12 months. LTI: long-term illness status for heart failure. TELESAT-HF, Eur J Heart Fail, 2025.

Relative effects, remote monitoring vs standard care
01 = standard care
All-cause mortality
HR 0.6495% CI 0.59–0.70−36%
Heart failure hospitalisations
RR 0.9595% CI 0.89–1.02no significant difference
Emergency visits
RR 0.8395% CI 0.75–0.92−17%
Intensive care admissions
RR 0.8495% CI 0.74–0.97−16%

TELESAT-HF, Eur J Heart Fail, 2025. Hazard ratio (HR) for mortality, rate ratio (RR) for events.

Logo TELESAT PRIOR-HF
Eur J Heart Fail · 2026 · doi 10.1093/ejhf/xuag146

TELESAT PRIOR-HF

HR 0.54All-cause mortality
95% CI 0.47–0.63; p < 0.001

That is a 46% lower risk of death in monitored patients (23.5% vs 39.6% deaths during follow-up): an association observed in real life.

Net zero: effective at neutral cost. A 46% lower risk of death, with no significant difference in total healthcare costs at 6, 12 and 24 months, remote monitoring fees included.
Question
Is remote monitoring associated with better survival in patients recently hospitalised for heart failure?
Population
3,579 patients hospitalised for heart failure in the previous 12 months: 1,258 monitored with Satelia® Cardio, 2,321 on standard care; mean age 73, 33% women.
Methods
Prespecified analysis of TELESAT-HF on SNDS data (August 2018 – December 2022), propensity score weighting, mean follow-up of about 20 months.
Other results
Heart failure hospitalisations: RR 0.85 (0.78–0.94). Admissions via emergency department: RR 0.68 (0.59–0.78). Intensive care admissions: RR 0.65 (0.53–0.79). Mean total healthcare costs: no significant difference at 6, 12 and 24 months.
What the study does not show. Observational study: propensity scoring corrects measured differences, not those absent from administrative databases. It does not establish causality and does not compare remote monitoring solutions with one another.
Survival from index date
Satelia® CardioStandard careHR 0.54 (95% CI 0.47–0.63)
5060708090100%0612182430
Months of follow-up

NNT = 6.2 to prevent one death at 30 months

Kaplan-Meier, curve redrawn from the article figure (vertical axis from 50%). TELESAT PRIOR-HF, Eur J Heart Fail, 2026.

Total healthcare costs per patient

Neutral cost: no significant difference at 6, 12 and 24 months

Standard careSatelia® Cardio
At 6 monthsp = 0.89, no significant difference
Standard care
€12,873
Satelia® Cardio
€13,067
At 12 monthsp = 0.43, no significant difference
Standard care
€19,022
Satelia® Cardio
€20,843
At 24 monthsp = 0.18, no significant difference
Standard care
€27,160
Satelia® Cardio
€31,374

Remote monitoring fees included. Amounts are numerically higher at 12 and 24 months in monitored patients, with no significant difference. TELESAT PRIOR-HF, Eur J Heart Fail, 2026.

Out of 100 patients followed
Standard care
40 deaths
Satelia® Cardio
24 deaths

Each dot is a patient; filled dots are deaths observed during follow-up: 39.6% on standard care vs 23.5% with remote monitoring, rounded. The adjusted hazard ratio (0.54) reflects a 46% lower instantaneous risk of death.

Relative effects, remote monitoring vs standard care
01 = standard care
All-cause mortality
HR 0.5495% CI 0.47–0.63−46%
Heart failure hospitalisations
RR 0.8595% CI 0.78–0.94−15%
Admissions via emergency department
RR 0.6895% CI 0.59–0.78−32%
Intensive care admissions
RR 0.6595% CI 0.53–0.79−35%

TELESAT PRIOR-HF, Eur J Heart Fail, 2026. Mean total healthcare costs: no significant difference at 6, 12 and 24 months.

Other results in three figures

A hospital programme, the safety of the algorithm and the patient experience.

Readmissions one year after enrolment

Optimum programme · 167 patients, median age 85 · conference abstract, Ann Cardiol Angeiol, 2023
−61%

heart failure readmissions in the year after enrolment.

Heart failure hospitalisations (167 patients):

Year before enrolment
163
Year after enrolment
63

Preliminary single-centre results (Médipôle Lyon-Villeurbanne), presented at a conference.

Negative predictive value of the algorithm

331 patients · J Cardiol Cardiovasc Med, 2023
99.43%

negative predictive value at seven days: when there is no alert, no hospitalisation follows.

Alert level of the 36,682 questionnaires:

Green (no alert)
95.3%
Orange
4.5%
Red
0.2%

Distribution of answers by the alert level computed by the algorithm. Questionnaire response rate: 90.9%.

Patient satisfaction

Survey of 825 patients, including 425 followed by phone with a nurse · Ann Cardiol Angeiol, 2023
94%

find the Satelia® Cardio application easy to use.

Patients followed by phone (425): follow-up is…

Simple
98.1%
Quick
98.1%
Useful
96.9%
Reassuring
96.7%
Complex
4.2%

Share of patients answering “yes”. Patients less comfortable with digital tools receive phone-assisted follow-up.

All publications

Peer-reviewed articles, from the most recent to the oldest.

2026
Mortality and use of care

TELESAT PRIOR-HF: mortality and use of care after a heart failure hospitalisation

Eur J Heart FailSNDS cohort, propensity score3,579 patientsMonzo L et al.

Key finding. Among 3,579 patients hospitalised for heart failure in the previous year, all-cause mortality was lower with remote monitoring (HR 0.54; 95% CI 0.47–0.63), with no significant difference in mean total healthcare costs at 6, 12 and 24 months.

Study summary

Prespecified analysis of TELESAT-HF restricted to patients hospitalised for heart failure in the year before inclusion. Using SNDS data and propensity weighting, about 1,258 monitored patients were compared with 2,321 patients on standard care. Remote monitoring was associated with lower all-cause mortality (23.5% vs 39.6%; HR 0.54), fewer heart failure readmissions (RR 0.85) and fewer days in hospital. Mean total healthcare costs did not differ significantly at 6, 12 and 24 months. Associations were consistent across age, sex and monitoring modality.

Summary written by Satelia from the published article.

2026
Specific populations

Diabetes and mortality in a nationwide cohort of monitored patients

Cardiovasc DiabetolNationwide cohort from monitoring data16,556 patientsValensi P et al.

Key finding. Among 16,556 monitored patients, diabetes was associated with moderately higher mortality (HR 1.16; 95% CI 1.06–1.27), no longer significant after adjustment for NYHA class.

Study summary

Retrospective cohort of adults followed in the Satelia® Cardio programme from 2018 to 2024 (NCT07561866): 16,556 patients, 28.5% with diabetes. Diabetes was associated with higher mortality in models without NYHA class, especially before age 75; the association weakened and was no longer significant after adjustment for NYHA class, available in a subgroup. Mortality was more closely related to severity, comorbidities and cumulative aetiologies. High ten-day weight variability, measured through monitoring, was associated with poorer survival: an exploratory marker.

Summary written by Satelia from the published article.

2026
Patients and satisfaction

Experience reported by 1,378 patients, from the ETAPES pilot to routine reimbursement

Healthcare (Basel)Repeated cross-sectional surveys1,378 patientsJourdain P et al.

Key finding. Under routine reimbursement, overall satisfaction was 80.3% among 978 patients surveyed in 2024, vs 77.0% in the 2020-2021 reference cohort (non-significant difference).

Study summary

Two independent surveys of Satelia® Cardio users: 400 digitally literate patients in 2020-2021, during the ETAPES programme, and 978 patients in 2024, after routine reimbursement began. Overall satisfaction remained high (80.3% vs 77.0%, non-significant difference) and 70.3% of respondents would recommend the service. In 2024, 30.1% of respondents were aged 80 or over; usability ratings were slightly lower in this group. As the two samples differ, no causal conclusion can be drawn.

Summary written by Satelia from the published article.

2026
Patients and satisfaction

Vaccination in monitored patients: reported knowledge and uptake

J Clin MedNationwide cross-sectional patient survey1,100 patientsJourdain P et al.

Key finding. Among 1,100 monitored patients surveyed in November 2025, 87.5% considered vaccination useful; for the 2025–2026 season, 62.2% reported influenza vaccination and 31.4% a COVID-19 booster.

Study summary

Electronic survey conducted from 5 to 28 November 2025 among Satelia® Cardio patients using the app: 1,100 respondents out of 4,856 invited (22.7%), mean age 71.5 years. 96% knew where to get vaccinated and 55.1% wanted reminders through remote monitoring. Lifetime reported vaccination was lower: 38.5% for the diphtheria-tetanus-pertussis-polio booster, 34.5% for pneumococcal vaccination and 11.5% for herpes zoster. Self-reported, descriptive data that identify groups to target in future prevention initiatives.

Summary written by Satelia from the published article.

2026
Treatments

SGLT2 inhibitor prescription in monitored patients: trends from 2021 to 2024

Int J CardiolNationwide cohort from monitoring data13,660 patientsMonzo L et al.

Key finding. Among 13,660 patients enrolled from 2021 to 2024, 64.4% were receiving an SGLT2 inhibitor at programme entry; prescription rose sharply after each major trial and guideline update, but remained lower in patients with chronic kidney disease.

Study summary

Analysis of adults with chronic heart failure enrolled in the nationwide Satelia® Cardio remote monitoring programme between 2021 and 2024 (NCT07022379): 13,660 patients, median age 78, 46% with reduced ejection fraction. SGLT2 inhibitor prescription at enrolment followed the major trials and ESC guidelines, with phenotype-specific patterns. It was more frequent in patients with diabetes, with a home-visiting nurse and in university hospitals, and less frequent with mildly reduced or preserved ejection fraction and chronic kidney disease, leaving room for optimisation.

Summary written by Satelia from the published article.

2026
Specific populations

Elder-SAT: predictors of early events in older patients after a hospitalisation

Heart Lung CircSingle-centre retrospective cohort, cardiogeriatric unit156 patientsMaurou O et al.

Key finding. Among 156 patients with a mean age of 86, 27.6% died or had an unplanned readmission within 90 days of discharge; elevated pulmonary arterial pressure was an independent predictor (adjusted HR 2.56; 95% CI 1.10–5.98), unlike ejection fraction and frailty.

Study summary

Single-centre retrospective cohort (cardiogeriatric unit, La Porte Verte hospital, Versailles) of 156 patients aged 65 and over hospitalised for acute heart failure and discharged with follow-up combining comprehensive geriatric assessment and Satelia® Cardio remote monitoring. Within 90 days, 7.1% died and 20.5% had an unplanned readmission. Elevated pulmonary arterial pressure was associated with these events; ejection fraction, classical geriatric markers and frailty were not independently associated. A preserved metabolic profile was associated with fewer readmissions.

Summary written by Satelia from the published article.

2026
Specific populations

REACT-HF: readmissions of very old patients in a cardiogeriatric pathway

Clin Interv AgingSingle-centre retrospective cohort, cardiogeriatric pathway255 patientsEsser R et al.

Key finding. Among 255 patients (median age 87) followed with Satelia® Cardio in a cardiogeriatric pathway, 24.7% were readmitted for heart failure within 12 months; at least moderate mitral regurgitation, absolute iron deficiency and COPD were associated with readmission.

Study summary

Single-centre retrospective cohort (cardiogeriatric department, Greater Paris area) of patients aged 65 and over enrolled in Satelia® Cardio remote monitoring at discharge after an acute heart failure hospitalisation, from April 2023 to August 2025, within a pathway combining coordinated outpatient follow-up and day-hospital care. Of 991 patients enrolled, 255 had sufficient 12-month follow-up. Heart failure readmissions reached 9.8% at 3 months, 16.1% at 6 months and 24.7% at 12 months; discharge loop diuretic dose, mitral regurgitation, iron deficiency and COPD were associated with readmission. A descriptive study without a control group: it does not allow conclusions on the effect of remote monitoring.

Summary written by Satelia from the published article.

2025
Mortality and use of care

TELESAT-HF: all-cause mortality at national scale

Eur J Heart FailSNDS cohort, propensity score18,882 patientsGirerd N et al.

Key finding. Across 18,882 patients from more than 300 centres, all-cause mortality was lower in monitored patients (HR 0.64; 95% CI 0.59–0.70); no significant difference in heart failure hospitalisations.

Study summary

Nationwide real-world cohort built on SNDS data from August 2018 to December 2022 (NCT06312501): 5,357 patients followed with Satelia® Cardio and 13,525 on standard care, from more than 300 centres, compared after propensity weighting. Follow-up combines a web interface with nurse phone monitoring for patients less comfortable with digital tools. All-cause mortality was lower in monitored patients (HR 0.64; 95% CI 0.59–0.70), with no difference in heart failure hospitalisations (RR 0.95), and fewer emergency visits and less time in hospital.

Summary written by Satelia from the published article.

2025
Specific populations

Remote monitoring of patients with a left ventricular assist device (LVAD)

Artif OrgansRetrospective multicentre study, 9 university hospitals161 patientsDelmas C et al.

Key finding. Among 161 patients with a left ventricular assist device followed in nine university hospitals, adherence was 79% over a mean follow-up of nearly 20 months.

Study summary

Nationwide retrospective study in nine university hospitals describing remote follow-up of 161 patients with a left ventricular assist device through a dedicated application. Mean age was 62; half of the patients were implanted as a bridge to transplant. Over a mean follow-up of 19.9 months, adherence reached 79%; the algorithm issued orange and red alerts, 48.5% of which were resolved. The authors conclude that remote follow-up is feasible in this subpopulation and call for prospective studies on survival and quality of life.

Summary written by Satelia from the published article.

2025
Clinicians and organisation

Experience and barriers reported by hospital teams

Hosp TopPilot study, semi-structured interviews379 patientsBenchimol H et al.

Key finding. In three hospitals in Nouvelle-Aquitaine (379 patients included), the barriers reported by clinicians were organisational: staffing, alert management and training of dedicated nurses.

Study summary

Descriptive study conducted from October 2022 to April 2023 in three hospitals, covering 379 heart failure patients (mean age 75.2) enrolled in a remote monitoring service. Semi-structured interviews with one cardiologist and two nurses describe broadly positive acceptance and barriers that are all organisational: staffing, handling alerts within tight schedules, initial reluctance from hospital administration, and the need for dedicated, trained nurses. The number of professionals interviewed is small.

Summary written by Satelia from the published article.

2024
Clinicians and organisation

Clinical impact and good practice: a case report

Patient Prefer AdherenceCase report1 patientCreton S et al.

Key finding. A reference weight entered incorrectly at enrolment silenced monitoring for fifteen months: enrolling a patient must be prepared as a step of the care pathway.

Study summary

Case of a 74-year-old patient followed at Cochin Hospital (AP-HP, Paris) for heart failure, hospitalised seven times in fifteen months without any remote monitoring alert. During the last stay, a telehealth nurse found that the reference weight entered at enrolment was wrong; after correction, no new episode occurred. The authors draw a good-practice rule: enrolling a patient means reviewing their care pathway, not just registering them. A single case, which cannot be generalised.

Summary written by Satelia from the published article.

2023
Patients and satisfaction

Perceptions and satisfaction of monitored patients

Ann Cardiol AngeiolSelf-reported survey825 patientsJourdain P et al.

Key finding. Among 825 patients, overall satisfaction was 87%; 98.1% of the 425 patients followed by phone found this follow-up simple and quick.

Study summary

Voluntary self-reported survey conducted during the ETAPES programme among 825 patients: 400 used the web application on their own and 425 were followed by phone with a nurse. 87% reported being satisfied, 94% found the application easy to use and 70% felt it helped their doctor follow them. 98.1% of patients followed by phone found this follow-up simple and quick. The authors highlight the need for assisted follow-up for patients less comfortable with digital tools.

Summary written by Satelia from the published article.

2023
Algorithm and safety

Safety and performance of the algorithm in real life

J Cardiol Cardiovasc MedRetrospective observational study331 patientsJourdain P et al.

Key finding. Among 331 patients, the algorithm’s negative predictive value for hospitalisation within seven days was 99.43%.

Study summary

Retrospective observational study of 331 patients followed with Satelia® Cardio for more than six months between September 2018 and June 2020, under ETAPES: 36,682 questionnaires, with a 90.9% response rate. The algorithm classifies each answer as green, orange or red: 95.3% of answers were green, 4.5% orange and 0.2% red. Its negative predictive value for hospitalisation within seven days was 99.43%. The study assesses the algorithm’s safety, i.e. how reliable the absence of an alert is, not its clinical effect.

Summary written by Satelia from the published article.

2022
Funding

ETAPES and Satelia® Cardio: an innovative funding programme

Digit HealthDescriptive analysisPages N et al.

Key finding. Description of the ETAPES pilot funding programme and its implementation with Satelia® Cardio, before remote monitoring entered routine reimbursement in 2023.

Study summary

Descriptive analysis, based on public official documents, of the ETAPES pilot funding programme (created in 2016, operational from 2018) and of the Satelia® Cardio solution. It details eligibility criteria for heart failure patients and the required therapeutic education, and notes that Satelia® Cardio relies on patient-reported symptoms, without any connected device. The ETAPES programme ended on 31 December 2022.

Summary written by Satelia from the published article.

Reading these studies critically

What you need to know to interpret the evidence.

All results are listed

This page lists all peer-reviewed work published on Satelia® Cardio, whether the results are favourable or neutral.

Observational studies

The nationwide analyses compare monitored and non-monitored patients in real life. No randomised trial has been published to date, and no study compares remote monitoring solutions with one another.

Declared conflicts of interest

Several authors are employees or collaborators of NP Medical, the manufacturer of Satelia® Cardio. Declarations are included in each publication.

Frequently asked questions

Is remote monitoring with Satelia® Cardio associated with lower mortality?

In TELESAT-HF (18,882 patients), all-cause mortality was lower in monitored patients (HR 0.64; 95% CI 0.59–0.70). This is an association observed in real life, not a randomised trial.

Where can I read the full articles?

Each publication links to the journal through its DOI; summaries are available on this site for the main studies.

How can I propose a research project?

Satelia’s medical department reviews collaboration proposals and data access requests.

A research project?

Working on heart failure remote monitoring, or want to discuss a study? Write to our medical department.